Skip to main content
. 2022 Jun 6;18(1):226–232. doi: 10.4103/1673-5374.344841

Figure 3.

Figure 3

Effects of different BR formulations on behavioral capacity tests in a mouse model of AD-like Aβ neurotoxicity.

(A) Spontaneous alternation behavior in the Y-maze test. (B, C) Novel object preference index at 1 (B) and 24 (C) hours. Data are expressed as mean ± SD (n = 9). ##P < 0.01, vs. sham group; *P < 0.05, **P < 0.01, vs. model group; †P < 0.05, ††P < 0.01 (one-way analysis of variance followed by the least significant difference post hoc test). AD: Alzheimer’s disease; Aβ: amyloid-β protein; BR: berberine hydrochloride; BR-S: BR solution; BR-CL: BR common nanoliposomes; BR-PL: BR PEGylated nanoliposomes; BR-Lf: BR PEGylated nanoliposomes with lactoferrin modified.